Overview

• Pfizer agreed to offer Medicaid most‑favored‑nation pricing and to align launch prices of new U.S. drugs with levels in other high‑income countries.
• The company will participate in TrumpRx.gov, a federal site expected in early 2026 that directs shoppers to manufacturers’ direct cash‑purchase channels rather than processing insurance.
• Officials highlighted reported discounts of roughly 40% to 85% on select Pfizer medicines for direct purchase, though the pricing formulas, drug lists and timing remain partly confidential.
• In return, Pfizer secured a three‑year reprieve from planned pharmaceutical tariffs after pledging about $70 billion for U.S. manufacturing and research, following threats of a 100% levy starting Oct. 1.
• Experts say effects for most insured patients are unclear because many already pay low copays and Medicaid enrollees often face minimal out‑of‑pocket costs, with Medicare not included in this announcement.